clofazimine has been researched along with Pneumonia in 7 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ." | 5.91 | Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023) |
| " The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea." | 3.69 | Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996) |
| " However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ." | 1.91 | Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023) |
| "Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated." | 1.72 | Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. ( Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022) |
| "Clofazimine is an antimicrobial agent that has activity in vitro against mycobacteria." | 1.46 | Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. ( Daley, CL; Levin, A; Martiniano, SL; Nick, JA; Sagel, SD; Wagner, BD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, F | 1 |
| Furuuchi, K | 1 |
| Hanada, K | 1 |
| Fujiwara, K | 1 |
| Uesugi, F | 1 |
| Hiramatsu, M | 1 |
| Yoshiyama, T | 1 |
| Shiraishi, Y | 1 |
| Kurashima, A | 1 |
| Ohta, K | 1 |
| Morimoto, K | 1 |
| Sriram, D | 1 |
| Wahi, R | 1 |
| Maggioncalda, EC | 1 |
| Panthi, CM | 1 |
| Lamichhane, G | 1 |
| Jadhav, K | 1 |
| Jhilta, A | 1 |
| Singh, R | 1 |
| Ray, E | 1 |
| Sharma, N | 1 |
| Shukla, R | 1 |
| Singh, AK | 1 |
| Verma, RK | 1 |
| Martiniano, SL | 1 |
| Wagner, BD | 1 |
| Levin, A | 1 |
| Nick, JA | 1 |
| Sagel, SD | 1 |
| Daley, CL | 1 |
| Ruth, MM | 1 |
| van Ingen, J | 1 |
| Jarand, J | 1 |
| Davis, JP | 1 |
| Cowie, RL | 1 |
| Field, SK | 1 |
| Fisher, DA | 1 |
| Prescott, LM | 1 |
7 other studies available for clofazimine and Pneumonia
| Article | Year |
|---|---|
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Topics: Clofazimine; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Diseases; Nontuberculous | 2022 |
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Microbial Sensitivity Tests; Mycobacteriu | 2022 |
Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation.
Topics: Animals; Clofazimine; Inflammation; Mice; Pneumonia; Respiratory Aerosols and Droplets; Tuberculosis | 2023 |
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child; Clofazimine; Dose-Respo | 2017 |
New insights in the treatment of nontuberculous mycobacterial pulmonary disease.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculous | 2017 |
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Etham | 2016 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 1996 |